| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2000;102:386.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Effect of Coumarins Started Before Coronary Angioplasty on Acute Complications and Long-Term Follow-Up
A Randomized Trial
Presented in part at the 21st Congress of the European Society of Cardiology (Hotline-1), Barcelona, Spain, August 28 through September 1, 1999, and the 72nd Scientific Sessions of the American Heart Association, Atlanta, Ga, November 7–10, 1999.
From the Department of Interventional Cardiology, St Antonius Hospital, Nieuwegein, and the University Hospital Nijmegen St Radboud (F.W.A.V), Netherlands.
Correspondence to J.M. ten Berg, MD, Department of Cardiology, St Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, Netherlands. E-mail jurtenberg{at}wxs.nl
Background—Coronary angioplasty frequently creates a thrombogenic surface, with subsequent mural thrombosis that may lead to acute complications and possibly stimulates the development of restenosis. Whether coumarins can prevent these complications is unclear. The objective of this open, randomized trial was to assess the clinical effect of coumarins started before coronary angioplasty and continued for 6 months.
Methods and Results—Before coronary angioplasty, 530 patients were randomly assigned to aspirin plus coumarins and 528 patients to aspirin alone. At the start of the angioplasty, the mean international normalized ratio was 2.7±1.1; during follow-up, it was 3.0±1.1. At 30 days, the composite end point of death, myocardial infarction, target-lesion revascularization, and stroke was observed in 18 patients (3.4%) treated with aspirin plus coumarin compared with 34 patients (6.4%) treated with aspirin alone (relative risk, 0.53; 95% CI, 0.30 to 0.92). At 1 year, these figures were 14.3% and 20.3%, respectively (relative risk, 0.71; 95% CI, 0.54 to 0.93). The incidence of major bleeding and false aneurysm during hospitalization was 3.2% and 1.0%, respectively (relative risk, 3.39; 95% CI, 1.26 to 9.11). The benefit of coumarins was observed in both stented and nonstented patients.
Conclusions—Coumarins in addition to aspirin started before PTCA and continued for 6 months was more effective than aspirin alone in the prevention of acute and late complications after coronary angioplasty. This benefit was accompanied by a small but significant increase in bleeding complications.
Key Words: angioplasty • warfarin sodium • anticoagulants
This article has been cited by other articles:
 |
|
 |
|
  P. P. Karjalainen, S. Vikman, M. Niemela, P. Porela, A. Ylitalo, M.-A. Vaittinen, M. Puurunen, T. J. Airaksinen, K. Nyman, T. Vahlberg, et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment Eur. Heart J., March 16, 2008; (2008) ehn099v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
|
|
S.E. Husted, B.K. Ziegler, and A. Kher Long-term anticoagulant therapy in patients with coronary artery disease Eur. Heart J., April 2, 2006; 27(8): 913 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. van der Heijden, I. C. D. Westendorp, R. K. Riezebos, F. Kiemeneij, T. Slagboom, L. R. van der Wieken, and G.-J. Laarman Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation J. Am. Coll. Cardiol., July 7, 2004; 44(1): 20 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Anand and S. Yusuf Oral anticoagulants in patients with coronary artery disease J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 62S - 69S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ambrose and E. E. Martinez A New Paradigm for Plaque Stabilization Circulation, April 23, 2002; 105(16): 2000 - 2004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt, M. E. Bertrand, P. B. Berger, P. L. L'Allier, I. Moussa, J. W. Moses, G. Dangas, M. Taniuchi, J. M. Lasala, D. R. Holmes, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting J. Am. Coll. Cardiol., January 2, 2002; 39(1): 9 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Ikeda, K. Shimada, J. M. ten Berg, J. C. Kelder, H.W. T. Plokker, B. A. Hutten, and F. W.A. Verheugt Oral Anticoagulation Therapy During and After Coronary Angioplasty Circulation, December 11, 2001; 104 (24): e150 - e150. [Full Text] [PDF]
|
|
|
|
|
|
J. M. ten Berg, J. C. Kelder, M. J. Suttorp, F. W. A. Verheugt, and H. W. Thijs Plokker Influence of planned six-month follow-up angiography on late outcome after percutaneous coronary intervention: A randomized study J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1061 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. t. Berg, B. A. Hutten, J. C. Kelder, F. W. A. Verheugt, and H. W. T. Plokker Oral Anticoagulant Therapy During and After Coronary Angioplasty : The Intensity and Duration of Anticoagulation Are Essential to Reduce Thrombotic Complications Circulation, April 24, 2001; 103(16): 2042 - 2047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Additional articles abstracted in ACP Journal Club Evid. Based Med., March 1, 2001; 6(2): 35 - 35. [Full Text]
|
|
|
|
 |
|
 Coumarins Improve PTCA Outcome Journal Watch Cardiology, October 13, 2000; 2000(1013): 10 - 10. [Full Text]
|
|